Question: What is the impact of pembrolizumab, associated or not to chemotherapy, on the outcomes of overall mortality (death from any cause) and adverse events in the treatment of patients with advanced NSCLC when compared to chemotherapy alone?11. Silvinato A, Floriano I, Bernardo WB – Advanced non-small cell lung cancer – treatment with Pembrolizumab - REV ASSOC MED BRAS 2019; 65(12):1423-1432
Answer: The treatment with Pembrolizumab, associated or not with chemotherapy, in adult patients with squamous or non-squamous NSCLC, locally advanced or metastatic, without previous systemic therapy, without mutations in the EGFR gene and gene rearrangement of the ALK, with a score of 0 or 1 in the ECOG performance scale, with at least one measurable lesion evaluated by Recist version 1.1, and PD-L1 expression [Tumor Proportion Score (TPS)] ≥1% (positive PDL-1). High quality of evidence.
REFERENCE
-
1Silvinato A, Floriano I, Bernardo WB – Advanced non-small cell lung cancer – treatment with Pembrolizumab - REV ASSOC MED BRAS 2019; 65(12):1423-1432
Publication Dates
-
Publication in this collection
03 June 2020 -
Date of issue
Mar 2020
